GenFleet Therapeutics Repurchases 265,000 H Shares for HKD 6.70 Million

Bulletin Express10-29

GenFleet Therapeutics (Shanghai) Inc. executed an on-market repurchase of 265,000 H shares on 29 October 2026, paying an aggregate HKD 6.70 million. The transaction occurred within a price range of HKD 24.68 to HKD 26.08 per share, translating to an average cost of approximately HKD 25.30 per share.

Following the buyback, issued shares excluding treasury stock fell 0.08 % to 350.05 million, while treasury shares rose to 1.58 million. The total number of issued shares remained unchanged at 351.63 million.

The purchase forms part of a shareholder mandate approved on 11 May 2026, which authorises the company to repurchase up to 37.04 million shares. Cumulative buybacks under this mandate now stand at 1.58 million shares, representing 0.43 % of the company’s issued share capital at the mandate date.

Under Hong Kong listing rules, GenFleet is subject to a moratorium on issuing new shares or disposing of treasury shares until 28 November 2026. Management confirmed that the repurchase complied with all applicable regulatory requirements and that no material changes have been made to the previously filed explanatory statement.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment